Cassava Sciences Inc (SAVA)
25.84
-0.37
(-1.41%)
USD |
NASDAQ |
Nov 04, 16:00
26.00
+0.16
(+0.62%)
After-Hours: 20:00
Cassava Sciences Cash from Financing (Quarterly): 101.39M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 101.39M |
| March 31, 2024 | 22.16M |
| December 31, 2023 | 1.143M |
| September 30, 2023 | 0.464M |
| June 30, 2023 | 0.889M |
| March 31, 2023 | 0.064M |
| December 31, 2022 | 47.34M |
| September 30, 2022 | 0.136M |
| June 30, 2022 | 0.119M |
| March 31, 2022 | 0.211M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.075M |
| June 30, 2021 | 1.274M |
| March 31, 2021 | 190.99M |
| December 31, 2020 | 70.61M |
| September 30, 2020 | 0.991M |
| June 30, 2020 | 0.236M |
| March 31, 2020 | 3.613M |
| December 31, 2019 | 5.866M |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | -0.06M |
| December 31, 2018 | -0.072M |
| September 30, 2018 | 12.27M |
| June 30, 2018 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2018 | 1.898M |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | -0.024M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | -0.214M |
| March 31, 2016 | -0.046M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.313M |
| March 31, 2014 | 0.066M |
| December 31, 2013 | 0.264M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 0.254M |
| March 31, 2013 | 0.006M |
| December 31, 2012 | -34.43M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 0.186M |
| March 31, 2012 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2021
190.99M
Maximum
Mar 2021
23.56M
Average
0.991M
Median
Sep 2020
Cash from Financing (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | -3.852B |
| Eli Lilly and Co | 211.30M |
| Seelos Therapeutics Inc | 0.742M |
| Biomarin Pharmaceutical Inc | -499.12M |
| EyePoint Pharmaceuticals Inc | 0.329M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.24M |
| Cash from Investing (Quarterly) | -0.029M |
| Free Cash Flow | -86.31M |
| Free Cash Flow Per Share (Quarterly) | -0.3954 |
| Free Cash Flow Yield | -7.66% |